STMN2 has been indicated to be differentially expressed in metastatic and non-metastatic samples of serous ovarian cancer, and high level of STMN2 is associated with poor prognosis of patients [16]. The gene discussed is STMN2; the disease is ovarian serous adenocarcinoma.